Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

A&E testing scheme finds thousands of people with HIV and hepatitis

The £20 million scheme means the testing programme, which started in April 2022, can run in 33 hospital emergency departments over three years.

Storm Newton
Tuesday 06 June 2023 19:01 EDT
The testing programme will run in 33 hospital emergency departments over three years (Peter Byrne/PA)
The testing programme will run in 33 hospital emergency departments over three years (Peter Byrne/PA) (PA Wire)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A new NHS pilot scheme in A&E departments has helped diagnose thousands of people with HIV and hepatitis.

As part of the programme, people in A&E who are having blood taken for any reason can offer an additional sample, which is then screened for HIV, hepatitis B and hepatitis C.

A positive test means patients are then given access to specialist support and a treatment plan.

According to NHS England, the pilot has helped almost 2,000 people infected with HIV or hepatitis who were previously undiagnosed.

About 470 who had been diagnosed but were not receiving care were also identified and offered treatment.

The £20 million scheme means the testing programme, which started in April 2022, can run in 33 hospital emergency departments over three years, NHS England said.

It has been incredible to see how opt-out testing has changed the lives of people living with HIV

Anne Aslett, Elton John AIDS Foundation

Professor Sir Stephen Powis, NHS national medical director, said: “Effective testing for blood-borne viruses is vital in helping us identify and treat more people living with HIV and hepatitis, so we are very pleased with the positive impact of our routine opt-out testing programme.

“Increasing the early detection and diagnoses of HIV, hepatitis and other blood borne viruses, enables us to provide people with better access to the latest and most effective life-saving medication, which can prevent long-term health issues and reduces the chance of unknown transmissions to others.”

Anne Aslett, chief executive at Elton John AIDS Foundation, added: “When the Elton John AIDS Foundation first piloted opt-out HIV testing in emergency departments in south London, the results were not only staggering, they also paved the way for opt-out HIV testing to go country wide.

“Since opt-out testing in the highest prevalence areas began last April, the system has diagnosed people from the ages of 18 to 85. It has been incredible to see how opt-out testing has changed the lives of people living with HIV.”

According to NHS data, 42% of HIV diagnoses in the UK are when the patient’s immune system is already significantly damaged.

Research shows people who received a late diagnoses are eight times more likely to die from the illness.

Richard Angell, chief executive at Terrence Higgins Trust, said expanding testing for HIV and hepatitis in A&E was “essential” to the organisation meeting its goal of ending new HIV cases by 2030.

He added: “The results from one year of opt-out testing in areas with very high HIV prevalence are above and beyond what anyone expected and have demonstrated an incredible return on investment.”

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in